314 related articles for article (PubMed ID: 29330943)
1. Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients.
Hendriks RJ; Dijkstra S; Smit FP; Vandersmissen J; Van de Voorde H; Mulders PFA; van Oort IM; Van Criekinge W; Schalken JA
Prostate; 2018 Apr; 78(5):336-342. PubMed ID: 29330943
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of total plasma cell-free DNA level and androgen receptor amplification in castration-resistant prostate cancer.
Kubota Y; Hatakeyama S; Yoneyama T; Yoneyama MS; Hamano I; Konishi S; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Ohyama C
World J Urol; 2021 Sep; 39(9):3265-3271. PubMed ID: 33675416
[TBL] [Abstract][Full Text] [Related]
3. Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer.
Mahon KL; Qu W; Devaney J; Paul C; Castillo L; Wykes RJ; Chatfield MD; Boyer MJ; Stockler MR; Marx G; Gurney H; Mallesara G; Molloy PL; Horvath LG; Clark SJ;
Br J Cancer; 2014 Oct; 111(9):1802-9. PubMed ID: 25144624
[TBL] [Abstract][Full Text] [Related]
4. Tumor fraction in cell-free DNA as a biomarker in prostate cancer.
Choudhury AD; Werner L; Francini E; Wei XX; Ha G; Freeman SS; Rhoades J; Reed SC; Gydush G; Rotem D; Lo C; Taplin ME; Harshman LC; Zhang Z; O'Connor EP; Stover DG; Parsons HA; Getz G; Meyerson M; Love JC; Hahn WC; Adalsteinsson VA
JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385733
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.
Beltran H; Romanel A; Conteduca V; Casiraghi N; Sigouros M; Franceschini GM; Orlando F; Fedrizzi T; Ku SY; Dann E; Alonso A; Mosquera JM; Sboner A; Xiang J; Elemento O; Nanus DM; Tagawa ST; Benelli M; Demichelis F
J Clin Invest; 2020 Apr; 130(4):1653-1668. PubMed ID: 32091413
[TBL] [Abstract][Full Text] [Related]
6. Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.
Mahon KL; Qu W; Lin HM; Spielman C; Cain D; Jacobs C; Stockler MR; Higano CS; de Bono JS; Chi KN; Clark SJ; Horvath LG
Eur Urol; 2019 Sep; 76(3):306-312. PubMed ID: 30466891
[TBL] [Abstract][Full Text] [Related]
7. Methylated APC and GSTP1 genes in serum DNA correlate with the presence of circulating blood tumor cells and are associated with a more aggressive and advanced breast cancer disease.
Matuschek C; Bölke E; Lammering G; Gerber PA; Peiper M; Budach W; Taskin H; Prisack HB; Schieren G; Orth K; Bojar H
Eur J Med Res; 2010; 15(7):277-86. PubMed ID: 20696638
[TBL] [Abstract][Full Text] [Related]
8. The investigation of GSTP1, APC and RASSF1 gene promoter hypermethylation in urine DNA of prostate-diseased patients.
Haluskova J; Lachvac L; Nagy V
Bratisl Lek Listy; 2015; 116(2):79-82. PubMed ID: 25665470
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
Sonpavde G; Agarwal N; Pond GR; Nagy RJ; Nussenzveig RH; Hahn AW; Sartor O; Gourdin TS; Nandagopal L; Ledet EM; Naik G; Armstrong AJ; Wang J; Bilen MA; Gupta S; Grivas P; Pal SK; Lanman RB; Talasaz A; Lilly MB
Cancer; 2019 May; 125(9):1459-1469. PubMed ID: 30620391
[TBL] [Abstract][Full Text] [Related]
10. Correlation between the expression of DNMT1, and GSTP1 and APC, and the methylation status of GSTP1 and APC in association with their clinical significance in prostate cancer.
Zhang W; Jiao H; Zhang X; Zhao R; Wang F; He W; Zong H; Fan Q; Wang L
Mol Med Rep; 2015 Jul; 12(1):141-6. PubMed ID: 25738352
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies.
Trock BJ; Brotzman MJ; Mangold LA; Bigley JW; Epstein JI; McLeod D; Klein EA; Jones JS; Wang S; McAskill T; Mehrotra J; Raghavan B; Partin AW
BJU Int; 2012 Jul; 110(1):56-62. PubMed ID: 22077694
[TBL] [Abstract][Full Text] [Related]
12. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients.
Henrique R; Ribeiro FR; Fonseca D; Hoque MO; Carvalho AL; Costa VL; Pinto M; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
Clin Cancer Res; 2007 Oct; 13(20):6122-9. PubMed ID: 17947477
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci.
Bastian PJ; Ellinger J; Wellmann A; Wernert N; Heukamp LC; Müller SC; von Ruecker A
Clin Cancer Res; 2005 Jun; 11(11):4097-106. PubMed ID: 15930345
[TBL] [Abstract][Full Text] [Related]
14. Cell-free DNA concentration and fragment size as a biomarker for prostate cancer.
Chen E; Cario CL; Leong L; Lopez K; Márquez CP; Chu C; Li PS; Oropeza E; Tenggara I; Cowan J; Simko JP; Chan JM; Friedlander T; Wyatt AW; Aggarwal R; Paris PL; Carroll PR; Feng F; Witte JS
Sci Rep; 2021 Mar; 11(1):5040. PubMed ID: 33658587
[TBL] [Abstract][Full Text] [Related]
15. Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation.
Franceschini GM; Quaini O; Mizuno K; Orlando F; Ciani Y; Ku SY; Sigouros M; Rothmann E; Alonso A; Benelli M; Nardella C; Auh J; Freeman D; Hanratty B; Adil M; Elemento O; Tagawa ST; Feng FY; Caffo O; Buttigliero C; Basso U; Nelson PS; Corey E; Haffner MC; Attard G; Aparicio A; Demichelis F; Beltran H
Cancer Discov; 2024 Mar; 14(3):424-445. PubMed ID: 38197680
[TBL] [Abstract][Full Text] [Related]
16. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
[TBL] [Abstract][Full Text] [Related]
17. Methylation of APC and GSTP1 in non-neoplastic tissue adjacent to prostate tumour and mortality from prostate cancer.
Richiardi L; Fiano V; Grasso C; Zugna D; Delsedime L; Gillio-Tos A; Merletti F
PLoS One; 2013; 8(7):e68162. PubMed ID: 23874531
[TBL] [Abstract][Full Text] [Related]
18. Combined hypermethylation of APC and GSTP1 as a molecular marker for prostate cancer: quantitative pyrosequencing analysis.
Yoon HY; Kim SK; Kim YW; Kang HW; Lee SC; Ryu KH; Shon HS; Kim WJ; Kim YJ
J Biomol Screen; 2012 Aug; 17(7):987-92. PubMed ID: 22511308
[TBL] [Abstract][Full Text] [Related]
19. Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients.
Moreira-Barbosa C; Barros-Silva D; Costa-Pinheiro P; Torres-Ferreira J; Constâncio V; Freitas R; Oliveira J; Antunes L; Henrique R; Jerónimo C
Clin Epigenetics; 2018 Oct; 10(1):132. PubMed ID: 30373654
[TBL] [Abstract][Full Text] [Related]
20. Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.
Cheng J; Holland-Letz T; Wallwiener M; Surowy H; Cuk K; Schott S; Trumpp A; Pantel K; Sohn C; Schneeweiss A; Burwinkel B
Breast Cancer Res Treat; 2018 May; 169(1):69-82. PubMed ID: 29340881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
